KORU Medical Q1 net sales up 15% to $6.2M, net loss widens to $2.5M, raises FY22 revenue guidance

KORU Medical Systems, Inc.

2022-Q1 EPS reported -$0.06 revenue$6,244,330

Net sales $6.24M (+15% YoY); domestic core up 13.2%, novel therapies $0.36M (including NRE).
GAAP net loss $2.5M (-$0.06 EPS) vs $1.3M loss (-$0.03 EPS) prior year; adjusted EPS -$0.05.
Gross margin 58.0% (-150bps) on higher raw material/labor costs; operating expenses $6.7M (+24% YoY).
Raises FY22 revenue guidance to $26.5-$27.0M (prev $26.0-$27.0M); reaffirms 60% gross margin exit run rate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.